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Abstract
Background: Claudins are tight junction proteins that are involved in tight junction formation and function. Previous
studies have shown that claudin-7 is frequently upregulated in epithelial ovarian cancer (EOC) along with claudin-3 and
claudin-4. Here, we investigate in detail the expression patterns of claudin-7, as well as its possible functions in EOC.
Methodology/Principal Findings: A total of 95 ovarian tissue samples (7 normal ovarian tissues, 65 serous carcinomas, 11
clear cell carcinomas, 8 endometrioid carcinomas and 4 mucinous carcinomas) were studied for claudin-7 expression. In real-
time RT-PCR analysis, the gene for claudin-7, CLDN7, was found to be upregulated in all the tumor tissue samples studied.
Similarly, immunohistochemical analysis and western blotting showed that claudin-7 protein was significantly
overexpressed in the vast majority of EOCs. Small interfering RNA-mediated knockdown of claudin-7 in ovarian cancer
cells led to significant changes in gene expression as measured by microarrays and validated by RT-PCR and
immunoblotting. Analyses of the genes differentially expressed revealed that the genes altered in response to claudin-7
knockdown were associated with pathways implicated in various molecular and cellular functions such as cell cycle, cellular
growth and proliferation, cell death, development, and cell movement. Through functional experiments in vitro, we found
that both migration and invasion were altered in cells where CLDN7 had been knocked down or overexpressed.
Interestingly, claudin-7 expression was associated with a net increase in invasion, but also with a decrease in migration.
Conclusion/Significance: Our work shows that claudin-7 is significantly upregulated in EOC and that it may be functionally
involved in ovarian carcinoma invasion. CLDN7 may therefore represent potential marker for ovarian cancer detection and a
target for therapy.
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Introduction
Ovarian cancer is the sixth leading cause of cancer deaths in
women worldwide [1]. Ovarian cancer is typically diagnosed as
advanced disease when therapeutic options are limited and the
prognosis very poor. The past several years have witnessed a
number of advances in our understanding of the molecular me-
chanisms involved in ovarian cancer progression [2],[3], although
much of the details remain unknown. Among the genes whose
expression is frequently altered in ovarian cancer are those
encoding the claudin family of tight junction proteins [4]–[7].
Claudins form the backbone of TJs and are therefore essential in
epithelial compartmentalization and in controlling solute transfer
across cell monolayers [8]–[10].
In cancer, normal TJ function and structure are typically altered
and the TJs themselves are frequently disassembled [11],[12].
Recent gene expression profiling studies have reported altered
expression of a number of TJ proteins in multiple cancers,
including several claudin proteins [4],[6]. For example, claudin-3
and claudin-4 are elevated in ovarian, prostate, uterine and breast
cancers, while claudin-1 is reduced in breast and prostate cancers.
Claudin-7 has been found downregulated in several cancers
including esophageal [13],[14], head and neck [15] and prostate
cancer [16]. Loss of claudin-7 was correlated with dedifferentia-
tion in several different cancers [16]–[19]. In breast cancer,
claudin-7 expression was also found to be decreased and inversely
correlated with tumor grade and metastatic disease [17],[18],
although there is evidence that claudin-7 may become re-
expressed in metastases [20],[21]. It has therefore been suggested
that the loss of claudin-7 is associated with a loss of cell adhesion
and increased metastasis [14],[17]. However, claudin-7 has also
been shown to be elevated in several cancers. For example,
claudin-7 is known to be elevated in ovarian cancer [22]–[27] as
well as other malignancies [28],[29]. The reason for the different
patterns of changes observed in different cancers is currently
unknown, but may be related to the exact roles of claudin-7 in
different malignancies, making elucidation of these roles an
important goal.
In this report, we first evaluate claudin-7 expression levels in
ovarian tissue samples and cell lines using western blotting, RT-
PCR, and immunohistochemistry and find that claudin-7 is widely
expressed in ovarian tumors. Using microarrays, we find that
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down and analysis of these genes suggests several pathways through
which CLDN7 may function in ovarian cancer. We show that
CLDN7 knockdown leads to a decrease in phospho-Erk and an
increase in Raf-1 levels, suggesting a possible pathway for claudin-7
signaling in ovarian cancer. In addition, we find that CLDN7
expression is associated with increased invasion, but decreased
migration in multiple cell lines providing a functional link to CLDN7
expression in ovarian carcinoma.
Results
CLDN7 transcript and protein levels are elevated in
ovarian cancer tissues
Recent work shows that, in addition to the CLDN3 and CLDN4
genes, CLDN7 is frequently elevated in ovarian cancer [22–26,30].
In order to clearly define the CLDN7 expression patterns in ovarian
cancer, microdissected ovarian tumors of various subtypes, as well
as cell lines were analyzed by real-time RT-PCR. CLDN7 mRNA
wasfound to be highly up-regulated inall four major ovarian cancer
subtypes (i.e. serous, mucinous, clear cell, and endometrioid)
compared with normal ovarian tissues (Figure 1A). The level of
overexpression varied tremendously and was found to be anywhere
from 2-fold to 50,000-fold. Indeed, 2-fold increase over HOSE-B
was observed in 2 of the normal ovary controls while 50,000-fold
overexpression wasseenin3serousovariancancertissues.CLDN7is
widely distributed in normal human tissues and its transcript was
found at relatively high levels in kidney, colon, lung, small intestine,
testis, placenta, salivary gland, thyroid, adrenal gland, pancreas,
prostate, liver, stomach, ovary and skin (Figure 1B). On the other
hand, muscle, brain, heart, spleen, uterus, blood leukocytes, bone
marrow, fetal brain, and fetal liver expressed lower levels of CLDN7
mRNA.
In order to investigate claudin-7 protein levels in ovarian
cancer, a panel of 29 primary ovarian cancer samples as well as 4
normal ovarian tissues was studied by immunoblotting (Figure 1C,
Table S1). Claudin-7 was absent in all the normal ovarian tissues,
but was found at high/moderate levels in 66% (19/29) of the
cancer samples. Claudin-7 was found expressed at low levels in
24% (7/29) of the cases, and was not detectable in 10% (3/29).
Figure 1. CLDN7 expression in ovarian carcinoma. A. The indicated ovarian carcinoma subtypes were tested for CLDN7 expression by RT-PCR
and the levels are shown relative to HOSE-B cells (an ovarian surface epithelial cell line immortalized with E6 and E7 [52]). B. CLDN7 expression in
normal tissues. The following tissues were analyzed: 1, Muscle; 2, Brain; 3, Heart; 4, Kidney; 5, Spleen; 6, Liver; 7, Colon; 8, Lung; 9, Small Intestine; 10,
Stomach; 11,Testis; 12, Placenta; 13, Salivary; 14, Thyroid; 15, Adrenal Gland; 16, Pancreas; 17,Uterus; 18, Ovary; 19, Prostate; 20, Skin; 21, Plasma Blood
Leukocytes; 22, Bone Marrow; 23, Fetal Brain; 24, Fetal Liver. The levels are shown relative to muscle and tissues with levels higher than 4-fold are
indicated on the graph. C. Immunoblot analysis of claudin-7 expression in 2 normal ovarian tissues (N1 and N2), 7 serous (S1, S2, S3, S4, S5, S6, and
S7), one clear cell (C1) and one endometrioid (E1) ovarian carcinomas. A total of 29 samples were tested by immunoblotting and representative
examples are shown. D. Immunohistochemistry of serous ovarian carcinomas. Selected ovarian carcinomas (S3, S4, S5, S6) and a normal ovarian
sample (N) are shown. Ovarian cancer samples stained with claudin-7 antibody (Cl-7) exhibit strong staining compared to negative controls staining
lacking primary antibody (-).
doi:10.1371/journal.pone.0022119.g001
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wasexpressedat high levelsinovarian cancer(Figure 1D). The IHC
study demonstrated that claudin-7 overexpression was restricted to
the cancer cells and did not involve the stroma. In addition, while
certain tumors exhibited significant membrane staining (S3 and S4),
others showed reduced staining at the membrane and high levels of
cytoplasmic staining.
CLDN7 is elevated in ovarian cancer cell lines and can be
located at the membrane or in the cytoplasm
In order to evaluate CLDN7 expression in cell lines, 7 cell lines
were evaluated by RT-PCR and immunoblotting (Figure 2A, B).
The CLDN7 transcript was not detected in the non-malignant
surface epithelium line HOSE-B, but was found in all the ovarian
cancer cell lines, except UCI101 and OVCA432 (Figure 2A).
Similarly, claudin-7 protein was not detected in HOSE-B, but was
present in most ovarian cancer cell lines (but not in HEY and
UCI101) (Figure 2B). Interestingly, HEY cells showed high CLDN7
mRNA levels, but low protein levels, while OVCA432 exhibited
very low CLDN7 transcript levels, but high claudin-7 protein
expression. These data show that while claudin-7 transcription is
retained in cell lines, claudin-7 protein levels may be regulated
through post-transcriptional mechanisms.
Using immunofluorescence, claudin-7 staining was found lo-
calized predominantly at the cell membrane, with punctate staining
in the cytoplasm of ovarian cancer cell lines BG-1, OVCA420 and
OVCA433 (Figure 2C). In OVCA432, we also observed membrane
staining, but little expression in the cytoplasm.
Gene expression changes following CLDN7 knockdown in
ovarian cancer cells
To investigate the possible roles of CLDN7 in ovarian cancer, we
examined gene expression changes following CLDN7 knockdown.
These knockdown experiments were performed in cell lines
OVCAR-2 and OVCA420, both of which exhibit moderate endo-
genous levels of claudin-7 expression (Figure 3A). CLDN7 siRNA
treatment led to a significant reduction in claudin-7 protein
72 hours following transfection (Figure 3A) and this time point was
chosen for microarray analysis. In OVCAR-2 cells, which form
TJs in culture, CLDN7 knockdown leads to a decrease in tran-
sepithelial resistance (TER, a measure of TJ tightness) and a con-
comitant increase in permeability across the monolayer (Figure
3B). This demonstrates that CLDN7 knockdown has a functional
effect on TJ in these cells. In OVCA420 cells, which do not form
TJ in culture, TER was extremely low and remained unaffected by
CLDN7 knockdown (Figure 3B). Consistent with this finding,
permeability was also unaffected by CLDN7 knockdown.
Microarray analysis was used to investigate the effects of CLDN7
knockdown on gene expression in both OVCAR-2 and OVCA420
cell lines. Clustering analysis demonstrated several patterns of
changes following CLDN7 knockdown and these patterns were
represented by 20 different clusters of genes as identified by
unsupervised pattern clustering using the JMP software (Figure
3C). CLDN7 was the only gene in cluster 3 and, as expected, was
highly downregulated in both cell lines. Of the 1327 genes
differentially expressed in the two lines (Table S2), 297 (200
upregulated and 97 downregulated) were shared by OVCAR-2
Figure 2. CLDN7 expression in ovarian cancer cell lines. A. Claudin-7 immunoblotting reveals high levels of expression in the indicated ovarian
cancer cell lines. B. RT-PCR analysis of CLDN7 mRNA in cell lines. C. Immunofluorescence of selected cancer cell lines shows strong claudin-7
expression at the cell junction in BG-1, OVCA433, OVCA420 and OVCA432, as well as punctuate cytoplasmic staining in BG-1 and OVCA420. Claudin-7
was detected with an anti-claudin-7 antibody and visualized with secondary antibody conjugated to Alexa fluor. Nuclei of cells were counterstained
with DAPI. Images were merged to determine correct localization.
doi:10.1371/journal.pone.0022119.g002
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differentially expressed genes, a figure much higher than that
expected by chance alone (p,0.001). In OVCAR-2, a total of 553
genes were upregulated and 415 were downregulated and in
OVCA420, 404 genes were upregulated and 252 were downreg-
ulated. The top 20 genes up-regulated and down-regulated in each
cell line (as well as in both simultaneously) are listed in Figure 4.
To validate and extend the microarray data, 15 genes that were
significantly altered by CLDN7 knockdown in one or both cell
lines, were chosen for validation by RT–PCR analysis (Figure 5).
While the fold expression appeared to be underestimated by
microarray analysis, real-time PCR confirmed the trends for all
the genes tested (Figure 5A, B). In addition, the protein levels for
several of these genes (CA12, RRAS2, PRSS8, APOE, AGT, SPRR3,
and CLDN7) were tested at different time points following CLDN7
knockdown (Figure 5C). The results of these experiments were
consistent with the changes observed by RT-PCR. Overall our
data show an excellent correlation between the changes detected
by microarrays and the corresponding protein expression levels.
Pathway analysis
Using Ingenuity Pathway Analysis (IPA), we analyzed the
pathways and possible functions associated with gene expression
changes following CLDN7 knockdown. Many of the top networks
identified involved cancer, cellular growth and proliferation, but
they were not clearly conserved between the cell lines (Table S3).
Interestingly, ‘‘integrin signaling’’ was found in both cell lines
among the most significant canonical pathways identified (Table
S3). The top biological functions included a variety of functions
such as cellular growth and cell death, and interestingly, cellular
movement. The physiological systems identified included hema-
tological and immune response, as well as connective tissue
Figure 3. CLDN7 knockdown and its effects on gene expression. A. Immunoblot analysis of OVCAR-2 and OVCA420 cells following CLDN7
knockdown for 72 hrs. B. Effects of CLDN7 knockdown on TJ and permeability. Transepithelial resistance (TER) was measured at multiple time-points
following CLDN7 knockdown. Permeability was measured by evaluating the ability of fluorescein-isothiocyanate-dextran (40 kDa) to cross the
monolayer. Fluorescence measurements reflect monolayer permeability and the results mirror the TER measurements. Experiments were performed
in triplicate and the results are shown as average +/2 S.E.M. An asterisk (*) indicates a p-value,0.05, and a double asterisk (**), a p-value,0.01. C.
Hierarchical clustering analysis of gene expression following CLDN7 knockdown in both cell lines. The green color represents down-regulation, while
red represents up-regulation. A total of 20 clusters of genes exhibiting distinct patterns were identified.
doi:10.1371/journal.pone.0022119.g003
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identified significant categories such as ‘‘structural molecule acti-
vity’’, ‘‘signal transducer activity’’, ‘‘transcription regulator acti-
vity’’, ‘‘translation regulator activity’’ and ‘‘transporter activity’’
(Table S4).
The possible functional relationships between the various
differentially expressed genes were then determined using a
variety of approaches. The 5 most significant common KEGG
pathways (as determined by Webgestalt) were ‘‘regulation of actin
cytoskeleton’’, ‘‘focal adhesion’’, ‘‘MAPK signaling pathway’’, and
‘‘insulin signaling pathway’’. Table S5 list all the pathways
identified. The top genes of the 5 most significant pathways listed
above were used to search the Pathway Studio database for known
protein-protein interactions (Figure 6A). Table S6 lists the protein-
protein interaction details and their corresponding references.
Interestingly one of the most prominent pathways identified
through this approach was the RAS-RAF-MAPK pathway
(Figure 6A). We then studied this pathway in OVCA420 cells by
examining Erk and Raf-1 expression and phosphorylation in these
cells (Figure 6B). Claudin-7 knockdown led to an increase in
phosphorylated Raf-1 (Ser-338) that was mirrored by an increase
in total Raf-1 at every time point, suggesting that indeed this
pathway could be affected by claudin-7. Erk1/2 levels were not
affected by claudin-7 knockdown, but phosphorylated Erk exhi-
bited a slight decrease, especially at later time points.
Claudin-7 protein expression is associated with cell
invasion, but inversely correlated with migration
Because our gene analysis above reveals cell movement as a
function possibly affected by CLDN7, we decided to test the
possible roles of CLDN7 in ovarian cancer cell migration and
invasion. We first performed transient siRNA-mediated knock-
down of CLDN7 expression in two ovarian cancer cell lines
(OVCAR-2 and OVCA420) and tested migration using the Oris
cell migration assay. CLDN7 knockdown led to a reproducible
increase in cell migration in both cell lines at every time point
tested (Figure 7A). Cell invasion was then evaluated using a
Boyden chamber assay and, as shown in Figure 7B, inhibition of
claudin-7 expression in OVCAR-2 and OVCA420 cells signifi-
cantly reduced the invasive potential of these cells. To further
confirm role of claudin-7 in invasion, claudin-7 was overexpressed
in OV-90 cells (which lack endogenous claudin-7 expression) and
Figure 4. Venn diagram showing the genes up-regulated and down-regulated in OVCAR-2 and OVCA420 following CLDN7
knockdown (absolute fold change.1.4). In the Venn diagram, numbers in red represent genes up-regulated and numbers in green represent
genes downregulated. The top 20 genes in each category are indicated in the table below the Venn diagram.
doi:10.1371/journal.pone.0022119.g004
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invasion compared to mock-transfected cells or parental OV-90
cells (Figure 7C).
Discussion
Our data show that CLDN7 is elevated at both mRNA and
protein levels in most ovarian cancer tissues and cell lines. By
western analysis, primary ovarian tumor tissues exhibited variable
expression of claudin-7 ranging from moderate to high expression
in 66%, low in 24%, and undetectable in 10% tumor tissue sam-
ples. The reason for this variability is unclear, as the transcrip-
tional regulation of CLDN7 remains largely unknown. Interesting-
ly, hypermethylation has be implicated in the downregulation of
CLDN7 expression in breast cancer [17] and two transcription
factors, Tcf-4 and Sox9, have been shown to cooperate in CLDN7
repression in colon cells [31]. It is unknown whether these
mechanisms are involved in CLDN7 regulation in ovarian cancer,
but these possibilities are currently under investigation.
We find that CLDN7 is elevated in all major subtypes of ovarian
cancer: serous, endometrioid, clear cell and mucinous. These
results are consistent with previous microarray data [22],[26] and
IHC experiments [27],[30] showing that CLDN7 is typically
overexpressed in epithelial ovarian cancer. Indeed, an early study
showed that claudin-7 is overexpressed in all epithelial ovarian
cancer subtypes, but is not overexpresssed in sex cord and stromal
tumors [23]. Moreover, a detailed analysis by Tassi et al. [24] has
shown that CLDN7 is universally up-regulated in epithelial ovarian
cancer at both the mRNA and protein levels. Our study also
demonstrates overexpression inthe most commonepithelial ovarian
cancer subtypes (serous, clear cell, endometrioid, and mucinous)
at both the mRNA and protein levels using qRT-PCR, IHC,
and immunoblotting. The use of immunoblotting and qRT-PCR
allows us to demonstrate that mRNA levels and protein levels are
not always correlated, suggesting post-translational regulation of
claudin-7 in ovarian cancer.
Interestingly, while we found that most claudin-7 staining was
localized to the membrane, several ovarian cancer samples
exhibited strong cytoplasmic staining (Figure 1D). The fact that
claudin proteins can be found in the cytoplasm has been reported
and in particular, punctate cytoplasmic staining of claudin-7 has
been observed in ovarian cancer [24]. The mechanisms and causes
of claudin cytoplasmic localization remain unclear but several lines
of evidence suggest that phosphorylation of claudins may affect
their localization. For example, mutation of a PKA phosphory-
lation site in claudin-3 has been shown to lead to an increased
cytoplasmic localization in ovarian cancer [32]. Similarly, claudin-
4 was found to be phosphorylated by protein kinase C and this
phosphorylation was found to lead to the translocation of claudin-
4 from the membrane to the cytoplasm and a decrease in TJ
function [32]. Claudin proteins are also known to be regulated by
palmitoylation, as claudin-14 palmitoylation has been shown to be
Figure 5. Validation of microarray data. A. Fold changes of the various indicated genes in OVCA420 and OVCAR-2 cells following CLDN7
knockdown. B. RT-PCR validation of the genes shown in (A). C. Immunoblotting analysis of selected candidates at various time points following
CLDN7 knockdown. GAPDH control was included to confirm similar loading in all the lanes.
doi:10.1371/journal.pone.0022119.g005
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whether claudin-7 can be modified and whether modifications can
affect its localization.
The overexpression of claudins in cancer suggests that claudins
might have functional roles in tumorigenesis. Several groups have
studied the possible roles of claudin-7 in cancer. Claudin-7 has
been suggested to be involved in the regulation of prostate specific
antigen (PSA) [34], possibly through interaction with junctional
adhesion molecule A (JAM-A) [35]. Claudin-7 has also been
reported to form a complex with EpCAM-tetraspanin which
interferes with EpCAM-mediated cell adhesion properties and
increases resistance to apoptosis [36–38]. Indeed, in colorectal
carcinoma, EpCAM and claudin-7 are found in association with
the tetraspanins CD9 and/or CO-029 and promote metastasis
formation [37]. Additionally, EpCAM-CLDN7 complex was
suggested to have role in migration, proliferation, apoptosis
resistance, metastasis, and tumorigenicity [37],[39].
In trying to gather additional clues regarding CLDN7 function in
ovarian cancer, we investigated gene expression changes following
CLDN7 knockdown. We hypothesized that downregulation of
CLDN7 may affect the downstream pathways affected by this
protein and ultimately lead to expression changes in the genes
regulated by these pathways. Between the two ovarian cancer cell
lines studied, we identified a total of 1296 genes that were
significantly altered following CLDN7 knockdown. Among these
genes, 297 were simultaneously found differentially expressed in
both lines. Analysis of these genes using Ingenuity Pathway
Analysis, led to the identification of several gene networks
containing genes related to the functional categories ‘‘cancer’’,
‘‘cell death’’, ‘‘cell cycle’’, ‘‘RNA trafficking’’, ‘‘cellular develop-
ment’’, ‘‘cell signaling’’, ‘‘cellular growth and proliferation’’, and
‘‘cellular movement’’. From the Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathway analysis, we selected the top 5
pathways that were altered in both OVCAR-2 and OVCA420
cell lines and generated a protein-protein interaction network map
for these pathways. Using pathway Studio, we found direct
interactions between 33 significantly upregulated or downregulat-
ed genes (Table S6). The interaction network showed a number of
genes that have oncogenic or tumor suppressor roles. For example,
RRAS2, which encode a Ras-related GTPase with transforming
potential similar to H-, K- and N-Ras, is a well-known oncogene
and has been implicated in the pathogenesis of human cancer. The
pathways that mediate RRAS2-induced tumorigenesis are not well
established, but phosphoinositide 3-kinase, p38 MAPK, and
mTOR pathways have been implicated [40]. Of particular
interest, RRAS2 and RRAS have been shown to promote
invasion via integrin signaling in breast epithelial cells [41].
We have previously shown that ovarian epithelial cells that
express claudin-3 and -4 show increased invasiveness in vitro [42],
which was mediated through MMP-2 overexpression. Similarly, in
hepatocellular carcinoma cells, claudin-10 expression promoted
cell survival, motility, and invasiveness, while matrix metallopro-
teinase 2 (MMP2) was up-regulated [43]. However claudins have
also been shown to reduce invasion as claudin-4 expression was
associated with a reduction in invasiveness in pancreatic cancer
cells [44]. Reduced expression of claudin-7 has been correlated
Figure 6. Pathways affected by CLDN7 knockdown. A. Pathway Studio analysis. Direct interactions of 33 significantly upregulated (red upward
arrow) or downregulated (green downward arrows) genes are shown. The legend for the different types of interactions is shown below the map. B.
Immunoblot analysis of Erk1/2, phospho-Erk1/2 (p-Erk) and Raf-1 and phospho-Raf (Ser-338) in OVCA420 at the indicated time points following
CLDN7 knockdown.
doi:10.1371/journal.pone.0022119.g006
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the esophagus and in colorectal cancer [13],[45]. In this study we
found that CLDN7 knockdown led to changes in the expression of
genes associated with various functions, including migration/
invasion. In particular, following up on the pathway analysis
results, we showed that Raf-1, a gene previously implicated in cell
migration [46],[47], was up-regulated following CLDN7 knock-
down (Figure 6). Erk-1 was not found significantly elevated in these
conditions, suggesting that Raf-1 may signal through other
downstream pathways in response to CLDN7 knockdown.
Based on our expression data, we then investigated the possible
roles of CLDN7 and found effects on invasion and migration in
vitro. Indeed, invasion capacity was significantly reduced after
CLDN7 knockdown and, conversely, it was found increased after
overexpression of CLDN7. Interestingly, migration was found to be
increased following CLDN7 knockdown (possibly because an
increase in Raf-1), and these apparently contradictory findings
(invasion vs migration) may explain previous observations in the
field. Indeed, the exact roles of claudin on invasion have remained
controversial, as some investigators observe positive effects of
claudins on invasion and others have found the opposite. Since
claudin proteins are known to activate MMPs [42,48], but also
have roles in cell-cell adhesion [9] and in migration (as shown
here), the net effect observed may represent the outcome of these
opposite effects on invasion. Our data suggest that while CLDN7
overexpression can decrease migration, the increase in invasion
due to other factors (such as increased MMP activation) is
dominant and leads to a net positive effect on cell invasion in our
Figure 7. Effects of CLDN7 on the migration and invasion of ovarian cancer cells. A. Migration assays in OVCAR-2 and OVCA420 cells. The
migration of cells with CLDN7 knocked down (dark bars) or control cells (white bars) was measured at different time point after the beginning of the
assay. B. Boyden chamber invasion assay of OVCAR-2 and OVCA420 cells with and without CLDN7 knockdown. The number of invading cells was
measured every hour for 6 hours. C. Invasion assays in a model of CLDN7 overexpression. Two stable lines, OV90-CLDN7 and OV90-CiNeo, as well as
untransfected parental OV90 cells were used to test changes in invasion following CLDN7 overexpression. For all the results shown in this figure, the
experiments were performed in triplicate and the results are shown as mean +/2 S.E.M. An asterisk (*) indicated a p-value,0.05, and a double
asterisk (**), a p-value,0.01.
doi:10.1371/journal.pone.0022119.g007
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and invasion are under investigation, but our data may explain
some of the discrepancies in the literature.
In summary, we find that CLDN7 is elevated in the vast majority
of ovarian cancers. We performed microarray analysis to identify
changes in gene expression associated with CLDN7 knockdown in
ovarian cancer. Interestingly, we found that many genes and
pathways affected by CLDN7 expression are involved in cancer cell
survival, growth, and invasion. Invasion and migration assays
demonstrated clear effects of claudin-7 on the invasive behavior of
ovarian cancer cells. Our microarray analysis provides several
possible mechanisms by which claudin-7 can affect cell migration
and invasion, and these different mechanisms are currently being
investigated. In addition to their tight junction function, claudin-7
may play important roles in a number of signaling pathways
involved in cancer, cellular growth, proliferation, and cell cycle.
Given its important role in ovarian carcinogenesis, CLDN7 may
have significant potential in diagnostic and therapeutic applications.
Materials and Methods
Ethics Statement
All human tissues were collected through an IRB approved
protocol (MedStar Research Institute IRB #2003-103). The tissues
were collected anonymously and this protocol was exempted from
the consent requirement.
Cell Lines and Tissue Samples
Ovarian cancer lines used in this study, BG-1, UCI-101, HEY,
OV90, OVCA420, OVCA432, OVCA433, OVCAR-2, OV-
CAR-3, and OVCAR-5 have been published [49–51]. All these
lines were derived from serous epithelial ovarian cancers. These
cell lines were cultured in McCoy’s 5A growth medium (Invi-
trogen, Carlsbad, CA) supplemented with 10% fetal bovine serum
(FBS) and antibiotics (100 units/ml penicillin and 100 mg/ml
streptomycin). HOSE-B, an ovarian surface epithelial cell line
immortalized with E6 and E7 [52], was cultured in RPMI1640
supplemented with 10% FBS, antibiotics and 5 gg/ml EGF. Cell
lines stably expressing CLDN7 were generated by transfecting
OV90 ovarian cancer cell line with pCIneo-CLDN7 using Fugene-
6, followed by selection in 500 mg/ml G418. Control stable lines
were also generated by transfecting OV90 with the pCIneo vector.
Two stable cell lines with control vector and three expressing
CLDN7 cell lines were used for this study.
Forty-four primary ovarian cancer tissue samples as well as
normal tissues were obtained through the Collaborative Human
Tissue Network Gynecologic Oncology Group (Children’s Hospi-
tal, Columbus, OH). In addition, twelve primary ovarian cancer
samples (from primary ovarian cancer tissues) were obtained from
the Department of Pathology at The Johns Hopkins Medical
Institutions (Baltimore, MD). cDNA from 24 serous carcinomas, 6
clear cell carcinomas, 6 endometrioid carcinomas and 4 mucinous
carcinomas were a generous gift from Dr. Kathleen R. Cho
(University of Michigan). Histological classification and other
available clinical information of the tissues used in this study can
be found in Table S1. A total of 24 normal tissue cDNAs (covering
the major organs) were purchased from BioChain (Hayward, CA)
for RT-PCR analysis.
Real-Time RT-PCR
RT-PCR was performed as previously described [53]. The
SYBR Green I assay and the GeneAmp 5700 Sequence Detection
System (Applied Biosystems, Carlsbad, California) were used
for detecting real-time PCR products. The primers for CLDN7
(forward, 59-AGAGCACGGGGATGATGAG; reverse, 59-CA-
CCCATGGCTATACGGGC) and GAPDH (forward, 59-GAA-
GGTGAAGGTCGGAGTC; reverse, 59-GAAGATGGTGATG-
GGATTTC) were designed to cross intron-exon boundaries to
distinguish PCR products generated from genomic versus cDNA
template. The microarray data was validated by RT-PCR. The
genes selected for validation represented a wide range of expres-
sion patterns (both in terms of direction and fold changes). The
sequence of the primers used for RT-PCR validation of the
microarray data is available from the authors. PCR reactions for
each template were done in duplicate in 96-well plates. The
comparative CT method (Applied Biosystems) was used to deter-
mine gene expression in each sample relative to the value observed
in the nonmalignant HOSE-B, using GAPDH as normalization
control.
Antibodies
Rabbit polyclonal claudin-7 was purchased from Zymed
Laboratories Inc (South San Francisco, CA). Mouse monoclonal
CA12, RRAS2, SPRR3, GAPDH and Rabbit monoclonal RAF1
were obtained from Abcam (Cambridge, UK). Rabbit monoclonal
anti-Ep-CAM (clone E144) antibodies were obtained from Novus
Biologicals (Littleton, CO). Mouse polyclonal PRSS8 and AGT
were obtained from Novus Biologicals and Mouse monoclonal
ApoE was obtained from Genetex (Irvine, CA). Peroxidase-linked
donkey anti-rabbit immunoglobulin and sheep anti-mouse IgG
horseradish antibodies were obtained from Amersham Biosciences




Immunoblotting was performed as previously described [42].
After SDS-PAGE and transfer, the PVDF membranes were
blocked and then probed with anti-claudin-7 antibody (Zymed)
diluted 1:200. The blots were then washed and incubated in
horseradish peroxidase-conjugated secondary antibody (anti-
mouse or anti-rabbit IgG, 1:10,000; Amersham Biosciences
Corp.). For detection, enhanced chemiluminescence was carried
out using the enhanced chemiluminescence kit (ECL; Amersham
Biosciences Corp.). Immunohistochemistry was performed using
the Ultravision detection system (Labvision, Fermont CA)
according to the manufacturer’s recommendations. Images were
acquired by Axiovision 3.1 software on a Zeiss Axiovert S100
microscope under 40 objective lens (Carl Zeiss, Thornwood, NY).
For immunofluorescence, HOSE-B, BG-1, OVCA420, OVCA
432, OVCA433, and OVCAR-2 were grown to 90% confluency
on glass slides and were washed with phosphate buffered saline
(PBS) followed by fixation with cold methanol for 10 min at
220uC, fixed cells were washed, blocked and incubated with
primary anti-claudin-7 antibodies in blocking buffer (mAb and
pAb anti-claudin-7 at 1:100) for 1 h. Slides were then washed and
incubated with Alexa fluor-conjugated secondary antibodies. Cells
were then incubated with DAPI for 2–3 min and then mounted in
Prolong gold antifade mounting medium (Invitrogen). Fluorescent
signal was examined and imaged using a LSM 510 Meta confocal
microscope (Zeiss, Thornwood, NY).
siRNA knockdown
Claudin-7 specific siRNA oligos were purchased from Ambion,
Inc. (Austin, TX). Cells cultured in 6-well plates were transfected
with siRNA duplexes using LipofectAMINE 2000 (Invitrogen)
according to the manufacturer’s instructions. Cells were treated for
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harvested for Western blot analysis, RNA preparation or used for
other assays.
TER Measurements and Permeability Assay
TER measurement and permeability assays were performed as
previously described [42],[54]. Briefly, for TER measurements,
cells were plated at a density of 1610
5 cells/well in 12-well
Transwell filters and TER was measured using a Millicell-ERS
epithelial V-ohmmeter (World Precision Instruments, New Haven,
CT) as previously described [42]. For the permeability assays, the
transport of fluorescein isothiocyanate-dextran (average mass
40 kDa, Sigma-Aldrich, St. Louis, MO) across a monolayer of
confluent cells was monitored as previously described [54].
Illumina Microarray
Total RNA, obtained using Trizol, was quantified and assessed
using the RNA 6000 Nano Kit and 2100 Bioanalyzer (Agilent
Technologies UK Ltd, West Lothian, UK). Biotinylated cRNA
was prepared using the Illumina RNA Amplification Kit (Ambion,
Inc., Austin, TX) according to the manufacturer’s directions
starting with approximately 500 gg total RNA. Hybridization to
the Sentrix HumanRef-8 Expression BeadChip (Illumina, Inc.,
San Diego, CA), washing and scanning were performed according
to the Illumina BeadStation 5006 manual (revision C). Microarray
data processing was done using Illumina Bead Studio software.
Microarray analysis was performed essentially as described [55].
Raw microarray data were subjected to filtering and z-normali-
zation. Sample quality was assessed using scatterplots and gene
sample z-score-based hierarchical clustering. Expression changes
for individual genes were considered significant if they met 4
criteria: z-ratio above 1.4 (or below 21.4 for down-regulated
genes); false detection rate ,0.30; p-value of the pairwise t-
test,0.05; and mean background-corrected signal intensity z-
score in each comparison group is not negative. This approach
provides a good balance between sensitivity and specificity in the
identification of differentially expressed genes, avoiding excessive
representation of false positive and false negative regulation [56].
Hierarchical clustering analysis of the significant genes was done
using the JMP 6.0.0 software. Pattern clustering was obtained by
unsupervised k-mean clustering to identify gene pattern combina-
tions. A total of 20 patterns were identified. All the microarray
data are MIAME compliant and the raw data were deposited in
GEO database (accession number GSE26055).
Bioinformatics analysis
Genes differentially expressed were analyzed using Ingenuity
Pathway Analysis (Redwood City, California) and the web-based
webgestalt pathway analysis (http://bioinfo.vanderbilt.edu/web-
gestalt) [57]. The network genes associated with biological
functions and/or diseases in the Ingenuity Pathways Knowledge
Base were considered for the analysis. We used significant selected
Human gene list as background gene list and multiple testing was
controlled by both ANOVA and FDR criteria. Fischer’s exact test
was used to calculate a p-value determining the probability that
each biological function and/or disease assigned to that network is
due to chance alone.
Invasion and migration assays
The cell invasion capabilities of siRNA-transfected cells were
determined using a modified Boyden chamber invasion assay [58]
essentially as described [42]. Experiments were repeated at least
four times, with triplicate samples in each experiment. The
migration assays were performed using the Oris Cell Migration
Assay system (Platypus Technologies, Madison WI). Silicone cell
stoppers were inserted in each well in a 96 well plate to prevent
attachment of the cells in the center of the well (2 mm diameter).
After 72 hours of transfection with control siRNA or CLDN7
siRNA, cells were treated with 5 mmol/L calcein-AM (Molecular
Probes, Eugene, OR) for 1 hour at 37uC. Cells were then
trypsinized and 50,000 viable cells were plated in each well of a
96-well plate and incubated at 37uC. After overnight incubation,
cell migration was measured by reading fluorescence in a
Cytofluor 4000 at different time points, starting immediately after
removing the stoppers (0 hour) for up to 72 hours. All assays were
performed in triplicate. The data is shown as mean +/2 S.E.M.
Statistical Analysis
2-tailed t-test analysis was performed to determine significance.
P values,0.05 were considered significant.
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